Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Chimagen Biosciences

Request full access

Developing innovative medicine to address the unmet medical needs in the area of oncology

Pudong, ChinaFounded 2016Biotech & Life Sciences

About Chimagen Biosciences

Chimagen Biosciences is a biotechnology firm focused on the discovery and development of therapeutic monoclonal antibodies. The company directs its research and clinical studies towards treatments for cancer and autoimmune diseases.

A significant development for the company is its clinical-stage therapy, CMG1A46, which is designed to target B cell-driven autoimmune diseases. This asset has attracted major attention from the pharmaceutical industry, culminating in an acquisition agreement with GlaxoSmithKline (GSK). Under the terms of the deal, GSK will acquire CMG1A46 for an upfront payment of $300 million, with the total value of the transaction potentially reaching $850 million. This event highlights the company's business model of developing high-value therapeutic candidates for acquisition by larger pharmaceutical corporations, thereby generating revenue through milestone payments and upfront fees.

Source: Dealroom company data

At a glance

Status
Operational
Employees
5
Open positions
None listed
Dealroom signal
80.6/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Oncology, Biotech and Pharma, DT and LS, science-based
Business model
Manufacturing
Client focus
B2C

Funding history

1 recorded event

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
LATE VCOther financing Oct 2024 $100M $400M GSK ↗
Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Growth signals

Chimagen Biosciences website traffic

Latest recorded traffic for Chimagen Biosciences is 650 monthly website visits, up 51.2% over the last three months. Chimagen Biosciences's team grew 25% over the past year.

Latest monthly visits650 3-month web change+51.2% 1-year team growth+25%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

CompanyHeadquartersStatusEmployeesTotal fundingValuation
BiomXCustomized phage therapies to eradicate harmful bacteria in chronic diseases Ness Ziona, Israel Operational 30 $113M $13M
Color HealthProvides technology, software, and clinical services to improve access to cancer screening, diagnosis, and care for large populations Burlingame, United States Operational
Omada HealthOnline programs combine world-class science, technology, and design to inspire and enable people everywhere to live free of chronic disease San Francisco, United States Operational
Science 37Uses advanced telemedicine technology and patient-centric innovative networked clinical research models to rapidly accelerate biomedical discovery and bring down the costs of clinical trials Morrisville, United States Acquired
LabcyteLab­cyte Inc. is the maker of Echo® Acoustic Liquid Handling systems for life sciences Sunnyvale, United States Acquired
MedCity NewsMedCity News - Healthcare technology news, life science current eventsMedCity News New York City, United States Operational
LipocalyxsiRNA and plasmid Transfection Reagents | VIROMER® Halle (Saale), Germany Operational
Redx PharmaA drug discovery and development company focused on improving the characteristics of existing drug classes to create best-in-class new drugs in two main areas, cancer and infectious disease Macclesfield, United Kingdom Acquired
Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Chimagen Biosciences in the Pudong ecosystem

Live from Dealroom

The Chimagen Biosciences office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

1 investor on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series B and later1 investor entered at this stage

  • GSK
Team profiled 1 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇨🇳 China50%
🇺🇸 United States50%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Chimagen Biosciences on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Chimagen Biosciences’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.